Diabetes 116 items

Studies

• KRAKEN: oral muvalaplin lowers Lp(a) by 82 to 86 percent on an intact-particle assay (Nicholls et al., JAMA 2025)JAMA · January 2025 9
• Baseline and on-statin Lp(a) predict events in statin trials: patient-level meta-analysis (Willeit et al., Lancet 2018)Lancet · October 2018 9
• Lp(a) molar concentration, not apo(a) size, drives cardiovascular risk; loss of Lp(a) raises diabetes risk: deCODE (Gudbjartsson et al., JACC 2019)J Am Coll Cardiol · December 2019 8
• Lp(a) and myocardial infarction across seven ethnic groups: INTERHEART (Paré et al., Circulation 2019)Circulation · March 2019 8
• The phenotypic consequences of genetically lowered Lp(a) (Emdin et al., JACC 2016)J Am Coll Cardiol · December 2016 8
• Lp(a) predicts coronary events but not stroke, and evolocumab benefits at any Lp(a): VESALIUS-CV (Monguillon et al., Circulation 2026)Circulation · June 2026 7
• Safety of low Lp(a): no excess of bleeding, malignancy, neurocognitive events or AF, but more diabetes: FOURIER (Gencer et al., EHJ 2026)Eur Heart J · June 2026 7
• Lp(a) and recurrent ASCVD in 273,770 US patients: risk rises continuously to a hazard ratio of 1.45 above 300 nmol/L (MacDougall et al., EHJ 2025)Eur Heart J · November 2025 7
• High Lp(a) accelerates low-attenuation (necrotic core) plaque progression on serial CT angiography (Kaiser et al., JACC 2022)J Am Coll Cardiol · January 2022 7
• Low Lp(a) and large apo(a) isoforms are causally linked to type 2 diabetes (Kamstrup and Nordestgaard, Lancet Diabetes Endocrinol 2013)Lancet Diabetes Endocrinol · November 2013 7
• 2021 Canadian Cardiovascular Society dyslipidaemia guidelines: Lp(a) once in a lifetime (Pearson et al., Can J Cardiol 2021)Can J Cardiol · August 2021 6
• Lp(a) causally affects coronary disease and HbA1c but not diabetes risk, UK Biobank phenome-wide MR of 425,677 (JACC Adv 2026)JACC Adv · March 2026 8
• Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled AnalysisJ Am Coll Cardiol · October 2025 8
• Alirocumab lowers both Lp(a) and LDL-C but they pull new-onset diabetes risk in opposite directions, cancelling out net effect, ODYSSEY OUTCOMES post-hoc analysis finds (Diabetes Care 2025)Diabetes Care · April 2025 8
• Mass General Brigham Lp(a) Registry finds diabetes plus elevated Lp(a) drives a nearly eightfold jump in annual cardiac event rate (Cardiovasc Diabetol 2024)Cardiovasc Diabetol · July 2024 8
• Very low Lp(a) raises new-onset diabetes and fatty liver risk in UK Biobank, but Mendelian randomisation finds no causal link (Atheroscler Plus 2024)Atheroscler Plus · July 2024 8
• Pooling MESA, CARDIA, JHS, FHS and ARIC over 21 years, top-decile Lp(a) raises ASCVD risk 46% overall and 92% in people with diabetes (J Am Coll Cardiol 2024)J Am Coll Cardiol · April 2024 8
• Every 50 mg/dL rise in Lp(a) raises cardiovascular death risk by up to 31%, a dose-response meta-analysis of 957,253 people across 75 studies (Eur J Epidemiol 2023)Eur J Epidemiol · January 2023 8
• Lp(a) risk is highest in Southern Europe and in people with diabetes, the BiomarCaRE consortium study of 56,804 Europeans (Eur Heart J 2017)Eur Heart J · August 2017 8
• Elevated Lp(a) and insulin resistance jointly double cardiovascular mortality risk in MASLD, UK Biobank analysis of 101,348 (Cardiovasc Diabetol 2026)Cardiovasc Diabetol · July 2026 7
• Lp(a) fluctuates substantially in youth with type 1 diabetes, challenging the single-lifetime-measurement paradigm, 286-patient cohort (Cardiovasc Diabetol 2026)Cardiovasc Diabetol · June 2026 7
• Lp(a) raises post-PCI cardiovascular risk mainly when pericoronary inflammation is high, machine-learning study (J Clin Lipidol 2026)J Clin Lipidol · June 2026 7
• Lp(a) above 50 mg/dL raises first MI risk mainly in women with type 2 diabetes, cohort of 2,967 (Diagnostics Basel 2026)Diagnostics (Basel) · May 2026 7
• Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk FactorsEur J Prev Cardiol · April 2026 7
• Triple lipid-lowering therapy after ACS cuts LDL-C 59% but raises Lp(a) 91%, Indian cohort of 345 (J Clin Lipidol 2026)J Clin Lipidol · March 2026 7
• Lp(a) and insulin resistance jointly raise cardiovascular risk 32%, UK Biobank cohort of 328,031 (J Am Heart Assoc 2026)J Am Heart Assoc · February 2026 7
• Lp(a) predicts ASCVD across glucose-metabolism status independent of CRP, UK Biobank cohort of 307,269 (Diabetes Obes Metab 2026)Diabetes Obes Metab · January 2026 7
• Elevated Lp(a) predicts higher baseline coronary plaque burden and faster low-attenuation plaque growth on serial CT angiography (Front Cardiovasc Med 2026)Front Cardiovasc Med · January 2026 7
• Dual-high Lp(a) and inflammatory-lipid index carries an 8-fold MACE risk in 1,910 ACS patients with type 2 diabetes (Front Cardiovasc Med 2026)Front Cardiovasc Med · January 2026 7
• Both very low and very high Lp(a) raise stroke recurrence risk in 3,311 diabetic stroke patients, U-shaped pattern from China's national registry finds (Diabetol Metab Syndr 2025)Diabetol Metab Syndr · November 2025 7
• Lp(a)'s link to MACE is significantly stronger in atherosclerotic patients with type 2 diabetes than without, 25,826-patient Korean cohort finds (Eur J Prev Cardiol 2025)Eur J Prev Cardiol · July 2025 7
• Adding Lp(a) boosts prediction of MACE and limb loss after lower-limb revascularisation in diabetic CLTI patients, pushing model AUC as high as 0.98 (Cardiovasc Diabetol 2025)Cardiovasc Diabetol · July 2025 7
• Higher Lp(a) predicts obstructive coronary disease only in asymptomatic people with diabetes, not without, 7,201-person CCTA study finds (Sci Rep 2025)Sci Rep · July 2025 7
• Elevated Lp(a) is significantly higher in diabetic retinopathy, and higher still in its proliferative form, meta-analysis of 7,007 subjects finds (Medicina (Kaunas) 2025)Medicina (Kaunas) · June 2025 7
• Only 0.5% of 150,083 Mexican tertiary-care patients were tested for Lp(a), and just 26% of those with elevated levels got risk-modifying treatment (Lipids Health Dis 2025)Lipids Health Dis · May 2025 7
• Higher Lp(a) predicts worse long-term outcomes after heart attack, especially in women and patients with diabetes or hypertension, meta-analysis of 30,027 patients finds (Rev Cardiovasc Med 2025)Rev Cardiovasc Med · May 2025 7
• High Lp(a) raises diabetic nephropathy risk 64% in type 2 diabetes, meta-analysis of 15 studies finds (Horm Metab Res 2025)Horm Metab Res · April 2025 7
• Diabetes and elevated Lp(a) interact multiplicatively, giving patients with both a 2.57-fold coronary heart disease risk, MESA study of 6,668 finds (Atherosclerosis 2025)Atherosclerosis · March 2025 7
• High Lp(a) is linked to diabetic peripheral neuropathy in Asian but not European studies, meta-analysis of 18,022 type 2 diabetes patients finds (Diabetol Metab Syndr 2025)Diabetol Metab Syndr · March 2025 7
• Meta-analysis of 20,271 patients finds Lp(a) above 30 mg/dL more than quadruples ASCVD risk in diabetics (Cardiovasc Diagn Ther 2025)Cardiovasc Diagn Ther · February 2025 7
• Elevated Lp(a) predicts higher baseline plaque burden and faster low-attenuation plaque growth in 1,694 diabetic patients on serial CT angiography (Eur Radiol 2025)Eur Radiol · February 2025 7
• Elevated Lp(a) doubles cardiovascular risk in familial hypercholesterolaemia but not in familial combined hyperlipidaemia, where diabetes dominates instead, 909-patient study finds (Nutr Metab Cardiovasc Dis 2025)Nutr Metab Cardiovasc Dis · January 2025 7
• Lp(a) at or above 180 mg/dL nearly triples MACE risk even after LDL-C targets are met in diabetic ACS patients post-PCI (Sci Prog 2025)Sci Prog · January 2025 7
• Elevated Lp(a) predicts both coronary disease severity and 7-year MACE risk in 4,332 patients with type 2 diabetes (Heliyon 2024)Heliyon · September 2024 7
• Mendelian randomisation finds genetically higher insulin causally lowers Lp(a), helping explain why low Lp(a) tracks with diabetes risk (Cardiovasc Diabetol 2024)Cardiovasc Diabetol · August 2024 7
• Meta-analysis of 227,178 subjects finds the highest Lp(a) concentrations carry 37% lower risk of incident type 2 diabetes (Horm Metab Res 2024)Horm Metab Res · May 2024 7
• Mendelian randomisation finds no causal link between Lp(a) and type 2 diabetes despite an inverse observational correlation, in 563,420 participants (Arch Med Sci 2024)Arch Med Sci · January 2024 7
• Elevated Lp(a) triples recurrent cardiovascular event risk in coronary patients with prediabetes or diabetes, across 5,257 patients (J Endocrinol Invest 2024)J Endocrinol Invest · September 2023 7
• Lp(a) independently predicts diabetic nephropathy with extreme statistical certainty in 6,993 type 2 diabetes patients (Front Endocrinol 2023)Front Endocrinol (Lausanne) · January 2023 7
• Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE TrialJAMA Cardiol · October 2020 7
• Low Lp(a) combined with high insulin resistance nearly doubles fatty liver disease risk, in 22,534 Korean adults (Atherosclerosis 2020)Atherosclerosis · July 2020 7
• Lp(a) predicts additional cardiovascular risk in people with diabetes or prediabetes, the ARIC study of 9,871 adults (Atherosclerosis 2019)Atherosclerosis · December 2018 7
• Diabetes lowers Lp(a) but raises PCSK9, and CETP inhibition with torcetrapib cuts Lp(a) by 11.1%, a clinical trial analysis (J Clin Lipidol 2018)J Clin Lipidol · October 2017 7
• Low Lp(a) below 7 mg/dL, not high Lp(a), raises type-2 diabetes risk, the Bruneck study combined with a meta-analysis of 74,575 people (Cardiovasc Diabetol 2017)Cardiovasc Diabetol · March 2017 7
• Mendelian randomisation applied to Lp(a) two decades ago proved causality for cardiovascular disease, aortic stenosis and diabetes, a review of Lp(a) genetics (Cardiovasc Drugs Ther 2016)Cardiovasc Drugs Ther · February 2016 7
• Lp(a) predicts diabetic retinopathy, with a five-fold higher risk when combined with poor glucose control, a prospective cohort of 787 patients with type 2 diabetes (J Clin Lipidol 2016)J Clin Lipidol · January 2016 7
• Higher Lp(a) is linked to lower diabetes risk in a Chinese cohort of 10,122 adults (J Lipid Res 2015)J Lipid Res · February 2015 7
• In people with type 2 diabetes, genetically high Lp(a) does not raise cardiovascular risk, unlike in the general population, a GWAS of 2308 diabetic patients (Eur Heart J 2012)Eur Heart J · September 2011 7
• Higher Lp(a) grade tracks with CAD, PAD, retinopathy and CKD but not stroke in Japanese type 2 diabetes, cohort of 1,465 (J Atheroscler Thromb 2026)J Atheroscler Thromb · May 2026 6
• Lp(a) lowers type 2 diabetes risk only in severe prediabetes, UK Biobank analysis (Diabetes Metab Syndr 2026)Diabetes Metab Syndr · April 2026 6
• Elevated Lp(a) raises MACE risk up to 4.3-fold after PCI, systematic review of 23,421 patients (Cureus 2026)Cureus · March 2026 6
• Lp(a) doubles peripheral arterial disease risk in type 2 diabetes, cohort of 590 (Br J Hosp Med Lond 2026)Br J Hosp Med (Lond) · January 2026 6
• Higher Lp(a) predicts contrast-induced nephropathy risk in 928 diabetic patients undergoing coronary angiography (Front Cardiovasc Med 2026)Front Cardiovasc Med · January 2026 6
• Lp(a) explains part of the residual vascular risk in diabetes, driving both macro- and microvascular damage, review argues (Int J Mol Sci 2025)Int J Mol Sci · November 2025 6
• The Lp(a) paradox: high levels drive atherosclerosis but very low levels may raise type 2 diabetes risk, review argues for a risk-benefit reckoning (Diabetes Res Clin Pract 2025)Diabetes Res Clin Pract · October 2025 6
• About 1 in 5 children with new-onset diabetes has abnormal Lp(a), and levels can fluctuate within months, challenging the 'measure once' assumption (J Endocr Soc 2025)J Endocr Soc · September 2025 6
• Lp(a) raises cardiovascular risk in diabetes yet paradoxically low Lp(a) predicts developing diabetes in the first place, review by Corral's group finds (Curr Opin Lipidol 2025)Curr Opin Lipidol · May 2025 6
• Adding Lp(a) to standard risk factors raises coronary calcium prediction accuracy from 0.741 to 0.755 in elderly diabetics, 486-patient study finds (Rev Cardiovasc Med 2025)Rev Cardiovasc Med · March 2025 6
• Elevated Lp(a) compounds subclinical atherosclerosis risk specifically in diabetic chest-pain patients in China (Cardiovasc Diagn Ther 2025)Cardiovasc Diagn Ther · February 2025 6
• Neither Lp(a) concentration nor apo(a) isoform size predicts new-onset diabetes in prediabetic adults, IT-DIAB study of 303 finds, challenging a general-population signal (Diabetes Metab 2025)Diabetes Metab · February 2025 6
• Unbiased clustering of 661 Portuguese adults reveals a distinct high-Lp(a) profile: older, male, hypertensive and diabetic (Front Cardiovasc Med 2025)Front Cardiovasc Med · January 2025 6
• Even mildly elevated Lp(a) doubles coronary heart disease risk in 591 patients with early-onset type 2 diabetes (Front Endocrinol 2025)Front Endocrinol (Lausanne) · January 2025 6
• Lp(a) above the 90th percentile predicts recurrent ischaemic stroke in 2,029 patients with type 2 diabetes but not in those without it (Diabetes Metab Syndr Obes 2025)Diabetes Metab Syndr Obes · January 2025 6
• In 2,247 Chinese T2DM patients, the combination of low adipose insulin resistance and high Lp(a) carries the lowest MASLD risk (Endokrynol Pol 2025)Endokrynol Pol · January 2025 6
• Meta-analysis of 11 studies links high Lp(a) to a doubled risk of diabetic retinopathy in type 2 diabetes (Int Ophthalmol 2024)Int Ophthalmol · November 2024 6
• Lp(a) and hs-CRP rise with age specifically in Chinese T2DM patients who also have coronary disease, across 900 participants (Heliyon 2024)Heliyon · November 2024 6
• Cardiac CT in 207 diabetic patients links elevated Lp(a) to high-risk plaque but not to perfusion or fibrosis (Eur Radiol 2025)Eur Radiol · July 2024 6
• Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylJ Am Coll Cardiol · April 2024 6
• Lp(a) falls as triglycerides rise above 300 mg/dL, but only without diabetes, obesity or familial hypercholesterolaemia, in 5,275 Spanish lipid-clinic patients (Clin Investig Arterioscler 2024)Clin Investig Arterioscler · December 2023 6
• The HellenicSCORE II+ improves 10-year cardiovascular risk classification by 4% when stratified by Lp(a), calibrated on the ATTICA cohort (Hellenic J Cardiol 2024)Hellenic J Cardiol · October 2023 6
• Antisense oligonucleotides and siRNAs cut Lp(a) by 98-101% in recent trials, though whether this reduces cardiovascular events remains unknown, a review (Expert Rev Cardiovasc Ther 2023)Expert Rev Cardiovasc Ther · April 2023 6
• In Chinese populations, elevated Lp(a) is linked to post-PCI thrombosis, aortic stenosis, stroke and diabetes, a review of a distinctive risk profile (Int J Biol Macromol 2023)Int J Biol Macromol · February 2023 6
• Higher Lp(a) predicts a 61% lower risk of new-onset type 2 diabetes in patients with familial combined hyperlipidaemia, a 9-year follow-up of 474 patients (J Clin Lipidol 2023)J Clin Lipidol · January 2023 6
• 13 of 17 studies link elevated Lp(a) to diabetic retinopathy risk in type 2 diabetes, a systematic review of 4,688 patients (Diab Vasc Dis Res 2023)Diab Vasc Dis Res · January 2023 6
• Lp(a) tracks worsening kidney function and predicts advanced CKD stage in 224 patients with diabetic kidney disease (J Diabetes Complications 2023)J Diabetes Complications · December 2022 6
• Nano-curcumin (80 mg/day) cuts Lp(a) and hs-CRP over 90 days in 64 type 2 diabetic patients with coronary artery disease, an RCT (Biofactors 2023)Biofactors · June 2022 6
• Elevated Lp(a) tracks with lipid-rich, vulnerable coronary plaque specifically in diabetic patients on statins, the REASSURE-NIRS registry of 312 patients (Atherosclerosis 2022)Atherosclerosis · April 2022 6
• Higher Lp(a) raises diabetic nephropathy odds by 63% in type 2 diabetes, a meta-analysis of 9,304 patients across 11 studies (Front Endocrinol 2021)Front Endocrinol (Lausanne) · January 2021 6
• Elevated Lp(a) doubles risk of declining kidney function, especially in diabetic and hypertensive patients, a prospective study of 6,257 Chinese adults (J Lipid Res 2020)J Lipid Res · July 2020 6
• An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialJAMA Cardiol · June 2020 6
• Lp(a) ranges from under 0.1 to over 100 mg/mL between individuals, and is higher in women, a review of its evolutionary origins and genetic determinants (Curr Med Chem 2017)Curr Med Chem · January 2017 6
• Elevated Lp(a) above 30 mg/dL affects 20-30% of the global population, a review of emerging Lp(a)-lowering therapies (Curr Opin Endocrinol Diabetes Obes 2016)Curr Opin Endocrinol Diabetes Obes · April 2016 6
• Adding L-carnitine to simvastatin lowers Lp(a) in type 2 diabetes, while simvastatin alone raises it, a randomised trial of 52 patients (Atherosclerosis 2006)Atherosclerosis · December 2005 6
• Glycated Lp(a) worsens blood clot-dissolving capacity in vascular cells more than native Lp(a), a mechanistic study relevant to diabetes (Atherosclerosis 2000)Atherosclerosis · June 2000 6
• Lp(a) and insulin resistance jointly predict atherosclerotic plaque with a U-shaped interaction, 10,753-person Chinese cohort (Lipids Health Dis 2026)Lipids Health Dis · July 2026 5
• GLP-1 receptor agonists and outcomes in obese or diabetic patients with Lp(a) above 50 mg/dL: a propensity-matched retrospective cohort (Int J Cardiol 2026)Int J Cardiol · May 2026 5
• Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET CohortsDiabetes Obes Metab · February 2026 5
• Adding Lp(a) to the EAS risk score improves CHD reclassification in type 2 diabetes, pilot study of 90 (J Assoc Physicians India 2026)J Assoc Physicians India · February 2026 5
• Optimal Lp(a) cutoff for cardiovascular disease drops to 70 mg/L in diabetic patients, comparative analysis finds (Front Endocrinol (Lausanne) 2026)Front Endocrinol (Lausanne) · January 2026 5
• Lp(a) predicts post-PCI cardiac events in coronary disease and diabetes, but evidence is inconsistent, review of four studies (Am J Med Sci 2026)Am J Med Sci · December 2025 5
• Lp(a) may drive diabetic kidney disease via TGF-beta fibrosis and podocyte injury, review of unresolved mechanisms (Diabetes Res Clin Pract 2026)Diabetes Res Clin Pract · December 2025 5
• Lp(a) of 97.5 mg/L predicts coronary heart disease in type 2 diabetes, and six months of rosuvastatin does not budge it (Rev Assoc Med Bras 2025)Rev Assoc Med Bras (1992) · January 2025 5
• Reduced thyroid hormone sensitivity tracks with higher Lp(a) in 1,097 euthyroid patients with type 2 diabetes (Front Endocrinol 2025)Front Endocrinol (Lausanne) · January 2025 5
• Review examines Lp(a)'s paradox in diabetes: high levels compound cardiovascular risk, but low levels may themselves predict diabetes (Curr Diab Rep 2024)Curr Diab Rep · May 2024 5
• Periodontal inflammation area correlates with both IL-6 and Lp(a) in diabetic patients, more strongly in those with retinopathy (World J Diabetes 2024)World J Diabetes · April 2024 5
• Elevated Lp(a) (>=30 mg/dL) is associated with higher sarcopenia risk in 426 patients with type 2 diabetes, regardless of sex (Diabetes Metab Syndr Obes 2024)Diabetes Metab Syndr Obes · January 2024 5
• High Lp(a) raises diabetic vascular complication risk while low Lp(a) predicts new-onset type 2 diabetes, a paradox reviewed (Expert Rev Endocrinol Metab 2024)Expert Rev Endocrinol Metab · January 2024 5
• Statin therapy masks the inverse relationship between kidney function and Lp(a) in 149 Japanese patients with type 2 diabetes (J Atheroscler Thromb 2024)J Atheroscler Thromb · August 2023 5
• Lower Lp(a) predicts new-onset diabetes, but whether the link is truly causal remains muddled by conflicting Mendelian randomisation studies, a review (Atherosclerosis 2022)Atherosclerosis · May 2022 5
• C-peptide outperforms Lp(a) as a cardiometabolic risk predictor in type 2 diabetes, a nested case-control study of 253 participants (PLoS One 2022)PLoS One · January 2022 5
• Whether Lp(a)-raising gene variants add predictive value beyond Lp(a) concentration itself remains controversial, a review of a decade of advances (Pharmacol Res 2021)Pharmacol Res · August 2021 5
• Low Lp(a) predicts new-onset diabetes, yet high Lp(a) still raises cardiovascular risk in people who already have it, a review of causes and consequences (Curr Opin Endocrinol Diabetes Obes 2021)Curr Opin Endocrinol Diabetes Obes · April 2021 5
• Low-cost lifestyle coaching, not just costly drugs, could help manage cardiovascular risk in people with elevated Lp(a), a review of behavioural approaches (Curr Opin Endocrinol Diabetes Obes 2021)Curr Opin Endocrinol Diabetes Obes · April 2021 5
• Uric acid and Lp(a) track with neurological damage severity in diabetic patients with penetrating-artery cerebral infarction (Pak J Pharm Sci 2026)Pak J Pharm Sci · January 2026 4
• In patients referred for coronary angiography, elevated Lp(a) tracks with premature and multivessel coronary disease but not hypertension or obesity (Herz 2024)Herz · April 2024 4
• Higher Lp(a) is independently associated with diabetic nephropathy in 767 Han Chinese patients with type 2 diabetes, though discriminative value is modest (PLoS One 2024)PLoS One · January 2024 4